Aurinia Pharmaceuticals v. Zydus Cadila: LUPKYNIS® Patent Consolidated Action
Aurinia Pharmaceuticals sued Zydus Cadila in New Jersey federal court over two patents protecting LUPKYNIS® (voclosporin), its FDA-approved treatment for lupus nephritis. The case was consolidated into lead action No. 25-2580 after 226 days, with all pre-trial proceedings — including discovery — now proceeding under a single docket.
LUPKYNIS® Generic Defence: Two-Patent Consolidation in New Jersey
On 21 April 2025, Aurinia Pharmaceuticals Inc. filed Case No. 2:25-cv-02893 in the District of New Jersey against Zydus Cadila, asserting infringement of US11622991B2 and US10286036B2 — two patents covering voclosporin compositions and methods of use underlying Aurinia’s LUPKYNIS® product. LUPKYNIS® is the first FDA-approved oral calcineurin inhibitor specifically indicated for adult patients with active lupus nephritis, a high-value indication with limited generic competition.
On 3 December 2025, the Court entered a consolidation order under Federal Rule of Civil Procedure 42(a), merging the above-captioned action with related proceedings into Civil Action No. 25-2580 as the lead case. The consolidation was unopposed by all parties and was granted on the basis of common questions of law and fact, with the court citing judicial economy. All future filings in the consolidated action must be made exclusively in the lead case docket.
The 226-day timeline to consolidation suggests these parallel ANDA-style patent proceedings moved efficiently to a coordinated structure — consistent with New Jersey’s active pharmaceutical patent docket. The public record does not disclose whether Zydus Cadila has filed an ANDA with a Paragraph IV certification, though the pattern of a brand manufacturer asserting two formulation patents against a single generic challenger is characteristic of Hatch-Waxman litigation. Substantive merits adjudication — claim construction, validity, and infringement determinations — remains pending in the lead action.
Filing to Case Consolidated in 226 days
226 days from filing to consolidation order — typical for ANDA patent cases ahead of first pre-trial milestones
What consolidation means: one docket, coordinated discovery, merits still live
Rule 42 consolidation — procedural merger, not a merits ruling
Consolidation under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single coordinated proceeding. It does not resolve any substantive claim. The court found common legal and factual issues across the related actions and no party opposed. All pre-trial steps — discovery, scheduling, case management — now run on the lead case docket (25-2580).
No merits adjudicationAurinia retains all patent claims — now on a single, streamlined front
Consolidation into a lead case typically benefits the patent holder by preventing inconsistent rulings across parallel dockets and reducing duplicative litigation costs. Aurinia’s two voclosporin patents — US11622991B2 and US10286036B2 — remain fully asserted. The unopposed nature of the consolidation order suggests both sides likely acknowledged efficiency gains, though Aurinia’s infringement claims are fully preserved.
Claims fully preservedZydus faces coordinated multi-patent challenge in one venue
For Zydus Cadila, consolidation means defending against both asserted patents simultaneously under a single scheduling order and discovery regime. While consolidation can reduce some procedural burden, it also concentrates Aurinia’s patent portfolio into a single, focused proceeding. Zydus’s invalidity and non-infringement positions for both patents will now be developed and tested on the same timeline.
Dual-patent defence consolidatedGeneric LUPKYNIS® entry timeline remains uncertain pending merits
Until the lead action (25-2580) reaches a merits determination, Zydus Cadila’s ability to launch a generic voclosporin product remains legally constrained. LUPKYNIS® targets adult lupus nephritis — a chronic, underserved indication — making the commercial stakes of this litigation significant for both the innovator and the broader payer and patient market. The consolidated schedule will govern when substantive rulings can be expected.
Generic launch remains blockedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US11622991B2 and US10286036B2 covering LUPKYNIS®Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Indian generic pharmaceutical manufacturer seeking to commercialise generic voclosporinSearch in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMMA CAPITANELLI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | ALEC WONG | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | JAMES T. PETERKA | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Lauren Brophy Cooper | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | LEAH M. BRACKENSICK | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | MICHAEL J. GAERTNER | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | SCOTT P. CLARK | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Theodora T. Mccormick | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Zhibin Li | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Baker Donelson | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Buchanan Ingersoll & Rooney, PC | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is a procedural instrument, not a merits determination. The court’s findings — common questions of law and fact, judicial economy, and the absence of any opposition — are standard prerequisites under Rule 42(a) and do not indicate any view on patent validity or infringement. The designation of Civil Action No. 25-2580 as the lead case means all substantive rulings, including claim construction and trial, will issue from that docket. This case record is now effectively closed as a standalone matter.
US11622991B2 & US10286036B2 — Voclosporin Formulations for Lupus Nephritis
US11622991B2 and US10286036B2 cover voclosporin — a novel calcineurin inhibitor — in formulations and methods of use indicated for adult patients with active lupus nephritis. Voclosporin is the active ingredient in LUPKYNIS®, the first FDA-approved oral calcineurin inhibitor for this indication. The application lineages (US17/713140 and US15/835219) suggest prosecution histories that span Aurinia’s clinical development programme, potentially creating meaningful claim differentiation across the two patents.
In the pharmaceutical IP landscape, layering a formulation patent (covering the drug composition itself) with a method-of-use patent creates compounding barriers for generic challengers. A generic manufacturer must design around both independently or successfully invalidate both to obtain clear commercial freedom. For the lupus nephritis indication — where LUPKYNIS® is the only approved oral calcineurin inhibitor — these two patents effectively function as the primary legal moat protecting a high-value, specialty drug franchise against premature generic erosion.
Should you run an FTO against US11622991B2 and US10286036B2?
Any company developing, formulating, or seeking to commercialise a generic or next-generation voclosporin product — or a calcineurin inhibitor intended for lupus nephritis — should conduct a freedom-to-operate analysis against both asserted patents before investing in regulatory filings or manufacturing scale-up. The consolidated litigation in New Jersey signals that Aurinia is actively enforcing this portfolio across multiple challengers simultaneously.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map claim scope across both US11622991B2 and US10286036B2, identify prosecution history estoppel, and flag potential design-around opportunities — all within a single workflow. Track the lead consolidated action (25-2580) in real time to monitor claim construction rulings that will redefine the enforceability boundaries of both patents.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Cases Involving Calcineurin Inhibitor and Lupus Nephritis Patents
Explore related pharmaceutical patent infringement actions in the District of New Jersey involving ANDA challenges to specialty drug formulation and method-of-use patents.
What this case signals for the pharmaceutical patent IP landscape
Multi-patent ANDA litigation in New Jersey is intensifying. Aurinia’s consolidation strategy offers a template for brand defence.
New Jersey remains the premier venue for pharmaceutical patent enforcement
The District of New Jersey consistently handles the highest volume of Hatch-Waxman patent cases in the US. Aurinia’s filing here — and the court’s swift consolidation — reflects an established judicial infrastructure familiar with ANDA litigation timelines, claim construction, and the 30-month stay regime. Generic challengers should anticipate experienced judges and well-developed local rules.
Two-patent assertion stacks the Hatch-Waxman clock against generic entry
Asserting both US11622991B2 and US10286036B2 against Zydus triggers separate validity and infringement analyses that must be resolved before generic launch can be cleared. Even if one patent falls, the second remains a barrier. Brand manufacturers increasingly layer formulation and method patents precisely to extend the litigation runway and the effective commercial exclusivity period.
Aurinia v Zydus — key questions answered
Case No. 2:25-cv-02893 was closed on 3 December 2025 via a consolidation order under Fed. R. Civ. P. 42(a). The action was merged with related proceedings into Civil Action No. 25-2580 (the lead case) for all pre-trial purposes. No merits ruling on patent validity or infringement was issued in this docket.
Aurinia asserted two patents: US11622991B2 (application No. US17/713140) and US10286036B2 (application No. US15/835219). Both patents cover voclosporin formulations and methods of use underlying Aurinia’s LUPKYNIS® product for adult patients with active lupus nephritis.
Consolidation under Fed. R. Civ. P. 42(a) merges actions sharing common questions of law or fact into a coordinated proceeding. It is procedural only — no patent claims are resolved. All future filings, discovery, and case management in the Aurinia v. Zydus matter now proceed exclusively under lead docket 25-2580 in the District of New Jersey.
The public record characterises this as a patent infringement action involving generic versions of LUPKYNIS® (voclosporin). The pattern — brand manufacturer asserting formulation and method patents against a single generic challenger over an FDA-approved specialty drug — is consistent with Hatch-Waxman ANDA litigation, though the specific ANDA filing details are not confirmed in the available public record.
LUPKYNIS® (voclosporin) is Aurinia’s FDA-approved oral calcineurin inhibitor indicated for adult patients with active lupus nephritis. It is the first product of its class approved for this indication. Its commercial exclusivity is protected by US11622991B2 and US10286036B2, which Aurinia is actively enforcing against generic challengers including Zydus Cadila in the District of New Jersey.
PatSnap Eureka searches patents and litigation data to answer instantly.